Sign in
Taking people in United StatesPhase 2

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

Key facts

Who runs it
BioAegis Therapeutics Inc.
Where
Augusta, Chicago, Hannibal, Hershey, Houston, Los Angeles, Louisville, New York, Pittsburgh, and Rochester, United StatesSee the 11 sitesAlso in 12 other countries, 66 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
600 people, planned
Started
3 Oct 2024
Expected to end
1 Mar 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Rhu-pGSN
  • normal saline
Record updated
20 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Infection followed within a week of documented bilateral infiltrates/opacities consistent with ARDS, as assessed by the admitting emergency department, clinic, intensivist, or ward physician or equivalent caregiver or a radiologist; Investigator or designee to note radiologic findings in the electronic case report form (eCRF); Radiology report and conclusion should be summarized in the eCRF; A digital copy of the radiograph uploaded and saved for review
  • Acute hypoxemic respiratory failure (moderate-to-severe ARDS) for ≤48 hours associated with suspected or confirmed infection (moderate-to-severe ARDS defined by the ratio of arterial pressure of O2 to the fraction of inspired O2 ≤150). Eligible subjects will be intubated for mechanical ventilation, receiving noninvasive ventilation by continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP), or on HFNO at least 30 L/min of 50% or greater inspired O2. Although it is expected that most eligible subjects will be receiving positive end-expiratory pressure (PEEP) or CPAP ≥5 cm H2O consistent with the original Berlin definition (ARDS Definition Task Force 2012), these measures will not be mandated as entry criteria
  • Age ≥18 years
  • Informed consent obtained from subject/next of kin/legal proxy
  • Clear or convincing evidence of a precipitating infection during the 7 days preceding the diagnosis of ARDS in the judgement of the screening or primary care team
  • During the course of the study starting at screening and for at least 3 months after their final study treatment:; Female subjects of childbearing potential must agree to use 2 medically accepted and approved birth control methods; Male subjects with a partner who might become pregnant must agree to use reliable forms of contraception (i.e., vasectomy, abstinence), or an acceptable method of birth control must be used by the partner; All subjects must agree not to donate sperm or eggs

Who cannot take part

  • Previous splenectomy
  • Any vaccination in the previous 30 days
  • Participation in an investigational clinical trial (e.g., device, drug, or biologic) in the previous 30 days
  • Active underlying cancer or treatment with systemic chemotherapy or radiation therapy during the last 60 days or likely to require similar treatments during the ensuing 6 months
  • Ongoing evidence or suspicion that heart failure, volume overload, pulmonary emboli, atelectasis, chronic lung disease, pleural effusion, cardiac tamponade, or constrictive pericarditis are materially contributing to the clinical or radiological findings bas assessed by the care team or Investigator; an echocardiogram is strongly recommended as part of standard care to exclude a significant contribution of systolic or diastolic heart failure and volume overload
  • Presence of systemic fungal, yeast, parasitic, or mycobacterial infection
  • Known allergy to study drug or excipients
  • Transplantation of hematopoietic or solid organs, graft versus host disease, or post-transplant lymphoproliferative disease
  • Unsuitable for study participation, in the opinion of the Investigator, because of chronic, severe, end-stage, or life-limiting underlying disease unrelated to current infection likely to interfere with management and assessment of ARDS, only comfort or limited (non-aggressive) care is to be given, or life expectancy <6 months unrelated to acute infection in the opinion of the Investigator
  • Current or planned receipt of extracorporeal membrane oxygenation (ECMO)
  • Pregnant or lactating women
  • Weight >125 kg
  • Chronic mechanical ventilation or dialysis

Where in United States

Also in 12 other countries, 66 sites

  • Wellstar MCG Augusta UniversityAugusta, United StatesContact: Marti Farrough, RNTaking people
  • Northwestern University - Pulmonary and Critical Care MedicineChicago, United StatesContact: Helen K Donnelly, MS, BSN, RN, CCRCTaking people
  • Hannibal Regional HospitalHannibal, United StatesContact: Lindsey Gander, RN CRCTaking people
  • Penn State Health Milton S. Hershey Medical CenterHershey, United StatesContact: Kylee KimbelTaking people
  • McGovern Medical School - UT Physicians Pulmonary Medicine - Texas Medical CenterHouston, United StatesContact: Elizabeth VidalesTaking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Vivian HweTaking people
  • University of Louisville Hospital - Jewish HospitalLouisville, United StatesContact: Julie BurmesterTaking people
  • University of Louisville Jewish HospitalLouisville, United StatesContact: Julie BurmesterTaking people
  • New York University Grossman School of MedicineNew York, United StatesContact: Natalia LeontovichNot yet recruiting
  • University of Pittsburgh Medical CenterPittsburgh, United StatesContact: Chelsea PeetTaking people
  • Mayo ClinicRochester, United StatesContact: Amy SchuchardTaking people

About the trial

What the trial wants to find out

BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.

The 2 groups in the trial

  • Rhu-pGSN TreatmentTreatment being tested

    Subjects will receive rhu-pGSN 24 mg/kg once, followed by 5 daily doses of 12 mg/kg based on actual body weight in addition to standard care .

    Treatment: Rhu-pGSN

  • Normal Saline PlaceboPlacebo, for comparison

    Subjects will receive 6 doses of normal-saline placebo in volumes equivalent to subjects given rhu-pGSN in addition to standard care.

    Treatment: normal saline

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2 Randomized Double-blind Placebo-controlled Study To Evaluate The Efficacy And Safety Of Adjunctive Recombinant Human Plasma Gelsolin With Standard Care For Moderate-to-Severe ARDS Due To Pneumonia Or Other Infections
Record updated
20 October 2026